These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8302733)

  • 1. Prognostic value of p53 protein expression in breast carcinomas.
    Hurlimann J
    Pathol Res Pract; 1993 Nov; 189(9):996-1003. PubMed ID: 8302733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cysteine proteinase inhibitor cystatin A in breast cancer.
    Kuopio T; Kankaanranta A; Jalava P; Kronqvist P; Kotkansalo T; Weber E; Collan Y
    Cancer Res; 1998 Feb; 58(3):432-6. PubMed ID: 9458085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
    Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
    Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on p53 immunolocalisation in breast cancer and its prognostic significance.
    Meenakshi A; Manoharan V
    Hum Antibodies; 1999; 9(3):171-6. PubMed ID: 10690631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques.
    Hurlimann J; Chaubert P; Benhattar J
    Mod Pathol; 1994 May; 7(4):423-8. PubMed ID: 8066070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
    Gursan N; Karakök M; Sari I; Gursan MS
    Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
    Moll R; Mitze M; Frixen UH; Birchmeier W
    Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas.
    Tuck AB; O'Malley FP; Singhal H; Tonkin KS; Harris JF; Bautista D; Chambers AF
    Arch Pathol Lab Med; 1997 Jun; 121(6):578-84. PubMed ID: 9199622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
    Bhargava V; Thor A; Deng G; Ljung BM; Moore DH; Waldman F; Benz C; Goodson W; Mayall B; Chew K
    Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma.
    Martinazzi M; Crivelli F; Zampatti C; Martinazzi S
    J Clin Pathol; 1993 Nov; 46(11):1009-10. PubMed ID: 8254086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin D in invasive ductal NOS, medullary, lobular and mucinous breast carcinoma. An immunohistochemical study.
    Bedner E; Harezga B; Osborn M; Domagała W
    Pol J Pathol; 1995; 46(1):11-5. PubMed ID: 7780691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors of invasive ductal breast carcinomas.
    Lialiaris TS; Georgiou G; Sivridis E; Kareli D; Tripsiannis G; Papageorgiou A; Chrisafi S; Kritsi Z; Giatromanolaki A
    J BUON; 2010; 15(1):79-88. PubMed ID: 20414932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 protein expression in human breast carcinoma: lack of prognostic potential for recurrence of the disease.
    Katoh A; Breier S; Stemmler N; Specht S; Blanock K; D'Amico F
    Anticancer Res; 1996; 16(3A):1301-4. PubMed ID: 8702254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
    Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
    Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of p53 expression in primary breast carcinomas.
    Naidu R; Yadav M; Nair S; Kutty KK
    Anticancer Res; 1998; 18(1A):65-70. PubMed ID: 9568057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p53 protein in infiltrating and in-situ breast carcinomas.
    Walker RA; Dearing SJ; Lane DP; Varley JM
    J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.
    Domagala W; Markiewski M; Harezga B; Dukowicz A; Osborn M
    Clin Cancer Res; 1996 Jan; 2(1):147-54. PubMed ID: 9816101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas.
    Puglisi F; Barbone F; Tell G; Aprile G; Pertoldi B; Raiti C; Kelley MR; Damante G; Sobrero A; Beltrami CA; Di Loreto C
    Oncol Rep; 2002; 9(1):11-7. PubMed ID: 11748448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.